Suberoylanilide hydroxamic acid

Suberoylanilide hydroxamic acid abbreviated as SAHA (suberoyl+anilide+hydroxamic acid) inhibits class I and class II HDACs at nanomolar concentrations and arrests cell growth in a wide variety of transformed cells in culture at 2.5-5.0 µM. This compound efficiently suppressed MES-SA cell growth at a low dosage (3 µM) already after 24 hours treatment. Decrease of cell survival was even more pronounced after prolonged treatment and reached 9% and 2% after 48 and 72 hours of treatment, respectively. Colony forming capability of MES-SA cells treated with 3 µM SAHA for 24 and 48 hours was significantly diminished and blocked after 72 hours.

Synonyms: Suberoylanilide hydroxamic acid; N1-hydroxy-N8-phenyl-octanediamide; SAHA; Octanedioic acid hydroxyamide phenylamide
Technical Data: Molecular Weight - 264.33; Molecular formula - C14H20N2O3; CAS No - 149647-78-9

Ordering Information: Product Number - EC-000.2057
Price and Availability: Inquire
This product is also available to buy in bulk quantities.

Special offer
We are pleased to offer you set of eight HDAC inhibitors* at the best current market price:
$600/8 inhibitors* x 10 mg
$1100/8 inhibitors* x 50 mg
$1450/8 inhibitors* x 100 mg
Shipping and handling costs: $150
Delivery time: 5-10 days by courier from stock.
This special sale is for limited time only
* - Suberoylanilide Hydroxamic Acid (SAHA); Entinostat (MS-275); Tacedinaline (CI-994); BML-210; M344; Mocetinostat (MGCD0103); PXD101; LBH-589.

References:
1. Marks, P.A., Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotech 25(1) 84-90 (2007). DOI: 10.1038/nbt1272
2. Takashi Kumagai, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. International Journal of Cancer. 2007 Aug 1;121(3):656-65. DOI: 10.1002/ijc.22558
3. Hrzenjak A, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49. DOI: 10.1186/1476-4598-9-49

Related service: collection of Histone Deacetylase Inhibitors.